Bionano Genomics, Inc. - Common Stock — Cash Flow (NASDAQ:BNGO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -38.31 M-71.93 M-124.82 M-125.18 M-68.92 M-16.34 M -19.3 M Cash from investing activities -2.45 M-278.06 M82.77 M24.16 M73.84 M-12.75 M 6.78 M Cash from financing activities 61.9 M336.11 M23.01 M113.81 M-13.69 M24.04 M 13.8 M Free cash flow -38.31 M-71.93 M-124.82 M-125.18 M-68.92 M-16.34 M -19.3 M

News

Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

Stock Market News, 5/13/26 – U.S Stock Futures Mixed Ahead of Inflation Data amid Middle East Uncertainty - TipRanks.com

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Earnings This Week – May 11-May 15, 2026 - TipRanks.com

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Bionano Genomics (NASDAQ:BNGO)

Bionano study shows optical genome mapping detects gene editing alterations

Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?

H.C. Wainwright reiterates Buy rating on Bionano Genomics stock with $7 target